Gland Pharma Ltd

Gland Pharma experienced a decline on February 14, 2025, following a brief period of gains, marking a trend reversal. The stock is trading near its 52-week low and below various moving averages, while its one-day performance contrasts with the broader market, which saw a smaller decline.

Gland Pharma has seen notable trading activity, reaching a new 52-week low while also hitting an intraday high. Despite a challenging month with a significant decline, the stock has outperformed its sector today. It is currently trading below all key moving averages, indicating ongoing bearish trends.

Gland Pharma has faced significant volatility, reaching a new 52-week low of Rs. 1412. The stock has declined 6.44% over the past two days and 28.62% over the past year, underperforming against the Sensex. It is currently trading below multiple moving averages, indicating ongoing challenges.

Gland Pharma's stock has faced notable challenges, declining significantly today and underperforming over the past month. Currently trading above its 52-week low, the stock is below key moving averages, indicating a sustained downward trend and lagging behind its sector performance.

Gland Pharma's stock has declined significantly, trading near its 52-week low and experiencing a cumulative drop of 5.7% over two days. The company has faced a 23.85% decrease in the past month, underperforming compared to the broader market, raising concerns among stakeholders in the pharmaceuticals sector.

Gland Pharma's stock has declined significantly, trading near its 52-week low and experiencing a cumulative drop of 5.7% over two days. The company has faced a 23.85% decrease in the past month, underperforming compared to the broader market, raising concerns among stakeholders in the pharmaceuticals sector.

Gland Pharma's stock has declined significantly, trading near its 52-week low and experiencing a cumulative drop of 5.7% over two days. The company has faced a 23.85% decrease in the past month, underperforming compared to the broader market, raising concerns among stakeholders in the pharmaceuticals sector.

Gland Pharma experienced a notable uptick on January 28, 2025, following a six-day decline, suggesting a potential trend reversal. The stock reached a high of Rs 1494 and a new 52-week low of Rs 1413.75, while trading below key moving averages and facing a significant monthly decline.

Gland Pharma has faced notable volatility, hitting a new 52-week low and experiencing a seven-day decline totaling 14.01%. Despite this, it outperformed its sector, which fell by 2.63%. The stock is trading below all major moving averages and has declined 24.08% over the past year.

Gland Pharma has faced significant volatility, reaching a new 52-week low and trailing its sector. The stock has declined consecutively over six days, totaling a drop of 10.34%. Over the past year, it has underperformed, with a decline of 21.25% compared to the Sensex's gains.

Gland Pharma's stock has reached a new 52-week low, declining significantly over the past six days and underperforming compared to its sector. The stock's trading levels are below various moving averages, reflecting a sustained bearish trend, while its monthly performance shows a notable drop compared to broader market indices.

Gland Pharma's stock has faced significant challenges, hitting a new 52-week low and marking five consecutive days of losses. Over the past month, it has underperformed compared to the broader market and its sector, indicating a sustained bearish trend amid a difficult trading environment.

Gland Pharma has reached a new 52-week low of Rs. 1589, reflecting ongoing challenges in the market. The company has underperformed its sector and experienced a cumulative drop of 4.77% over the past five days. Additionally, it has declined 15.67% over the past year, contrasting with the Sensex's gains.

Gland Pharma has recently experienced a change in evaluation, reflecting shifts in its financial performance. The company's profit metrics for Q2 FY24-25 show a contraction, while capital efficiency indicators raise concerns about return generation. The stock has struggled over the past year, contrasting with broader market performance.

Gland Pharma has experienced a notable decline, marking its sixth consecutive day of losses with a cumulative drop of 9.45%. The stock is currently trading below its moving averages across various time frames, contrasting with broader market trends, including the Sensex's performance over the same period.

Gland Pharma has recently undergone a revision in its score, reflecting the stock's ongoing challenges in the market. Despite a modest gain over the past month, the stock has struggled, underperforming its sector and experiencing a notable decline in recent trading sessions. Gland Pharma has been added to MarketsMOJO's list, indicating a potential for future evaluation.

Gland Pharma has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock has shown resilience, outperforming its sector and maintaining a positive trend above key moving averages. This adjustment highlights Gland Pharma's consistent growth and stability in the pharmaceuticals sector.

Gland Pharma has recently experienced a revision in its score by MarketsMOJO, reflecting changes in its financial metrics and market position. Despite a stable financial structure indicated by a low debt-to-equity ratio, the stock's technical trend remains sideways, and it has faced challenges in long-term growth. Gland Pharma has been added to MarketsMOJO's list, highlighting its significance in the pharmaceuticals sector.

Gland Pharma has recently experienced a revision in its score by MarketsMOJO, reflecting concerns over its financial performance. The company's operating profit has declined significantly, and its latest quarterly results indicate a historical low in return on capital employed. Gland Pharma has been added to MarketsMOJO's list, highlighting the need for investors to reassess their positions.